Apyx Medical Corporation to Participate in Upcoming November Investor Conferences
Rhea-AI Summary
Apyx Medical (NASDAQ:APYX) announced that President and CEO Charles Goodwin and CFO Matt Hill will attend investor meetings in New York in November 2025.
They will participate in 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at Sheraton NY Times Square, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 at Westin NY Grand Central.
Investors seeking meetings should contact their Craig Hallum or Canaccord Genuity representatives. The release also restates the company’s Helium Plasma Platform products (Renuvion, AYON Body Contouring System, J-Plasma), notes >90 clinical documents supporting Renuvion and J-Plasma, and describes AYON as FDA-cleared.
Positive
- None.
Negative
- None.
News Market Reaction – APYX
In the Oct 27 session, APYX declined 2.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEARWATER, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conferences:
Event: 16th Annual Craig-Hallum Alpha Select Conference
Date: Tuesday, November 18, 2025
Location: Sheraton NY Times Square Hotel, New York, NY
Format: 1x1 Meetings
Event: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Date: Thursday, November 20, 2025
Location: Westin NY Grand Central, New York, NY
Format: 1x1 Meetings
To request a meeting with Apyx, investors should contact their Craig Hallum and Canaccord Genuity representatives.
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The AYON Body Contouring System™ is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
